Hourvitz A, Mosseri R, Solomon A, Yehezkelli Y, Atsmon J, Danon Y L, Koren R, Shouval D
Medical Corps, Israel Defence Forces, Jerusalem, Israel.
J Viral Hepat. 1996 Jan;3(1):37-42. doi: 10.1111/j.1365-2893.1996.tb00079.x.
A new vaccine against hepatitis B virus (HBV) infection, produced in mammalian Chinese hamster ovary (CHO) cells, contains the small(s), middle (Pre S2) and large (Pre S1) surface proteins of HBV. Three injections of a 5-micrograms or 10-micrograms dose were administered intramuscularly (i.m.) at 0, 1 and 6 months to a group of 105 young adults, who were monitored for a period of 6 months after the third injection. Seroconversion rates were 100% after the second injection of the 5-micrograms or 10-micrograms dose. Geometric mean titres of HBsAb at 1 month after the third injection were 12,156 mIU ml-1 and 13,482 mIU ml-1 in those receiving the 5-micrograms and 10-micrograms dose respectively. The vaccine was well tolerated with no significant adverse events. These preliminary results suggest that the Pre S-s recombinant vaccine, produced in mammalian cells, is highly immunogenic, leading to 100% seroconversion in the population tested after injection of only two doses of 5 micrograms.
一种在哺乳动物中国仓鼠卵巢（CHO）细胞中生产的新型乙型肝炎病毒（HBV）感染疫苗，包含HBV的小（S）、中（前S2）和大（前S1）表面蛋白。对一组105名年轻成年人在0、1和6个月时进行三次肌肉注射（i.m.），剂量分别为5微克或10微克，并在第三次注射后监测6个月。第二次注射5微克或10微克剂量后血清转化率为100%。在接受5微克和10微克剂量的人群中，第三次注射后1个月时HBsAb的几何平均滴度分别为12,156 mIU/ml和13,482 mIU/ml。该疫苗耐受性良好，无明显不良事件。这些初步结果表明，在哺乳动物细胞中生产的前S重组疫苗具有高度免疫原性，在仅注射两剂5微克后，受试人群中的血清转化率达100%。
